Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Shares Issued (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Shares Issued for 15 consecutive years, with $38000.0 as the latest value for Q4 2025.

  • Quarterly Shares Issued rose 100.79% to $38000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $13.6 million for FY2025, N/A changed from the prior year.
  • Shares Issued hit $38000.0 in Q4 2025 for Ani Pharmaceuticals, down from $9.8 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $79.1 million in Q3 2023 to a low of -$4.8 million in Q4 2024.
  • Historically, Shares Issued has averaged $9.6 million across 5 years, with a median of $1.0 million in 2024.
  • Biggest five-year swings in Shares Issued: soared 40875.15% in 2021 and later crashed 101.0% in 2022.
  • Year by year, Shares Issued stood at $69.2 million in 2021, then plummeted by 101.0% to -$690000.0 in 2022, then soared by 11565.07% to $79.1 million in 2023, then tumbled by 106.05% to -$4.8 million in 2024, then surged by 100.79% to $38000.0 in 2025.
  • Business Quant data shows Shares Issued for ANIP at $38000.0 in Q4 2025, $9.8 million in Q3 2025, and $1.2 million in Q2 2025.